^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BI 765049

i
Other names: BI 765049, B7-H6/CD3 T-cell engager, OBT624, BI765049, OBT 624, BI-765049, OBT-624
Associations
Company:
Boehringer Ingelheim, Oxford BioTherap
Drug class:
CD3 agonist, B7-H6 inhibitor
Related drugs:
Associations
29d
Enrollment closed • Enrollment change • Metastases
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049
4ms
Enrollment change • Metastases
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049
9ms
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Having the B7-H6 Marker (clinicaltrials.gov)
P1, N=120, Recruiting, Boehringer Ingelheim | Trial completion date: May 2025 --> Dec 2028 | Trial primary completion date: May 2025 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049
10ms
Enrollment open
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049
12ms
Trial primary completion date
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049
12ms
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
P1, N=70, Not yet recruiting, Boehringer Ingelheim | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Nov 2025 --> Dec 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049
1year
Trial initiation date • Combination therapy • Metastases
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049
1year
New P1 trial • Combination therapy • Metastases
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049
over1year
Trial completion date • Metastases
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049
over1year
Trial primary completion date • Metastases
|
NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
ezabenlimab (BI 754091) • BI 765049